Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Sreyashi Basu et al.|Cancer Discovery|2018Cited by 570
Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscapePrajwal Boddu, Manoj M. Pillai|Molecular Cell|2024Cited by 32